[go: up one dir, main page]

PE20240693A1 - Receptores de celulas t - Google Patents

Receptores de celulas t

Info

Publication number
PE20240693A1
PE20240693A1 PE2023002239A PE2023002239A PE20240693A1 PE 20240693 A1 PE20240693 A1 PE 20240693A1 PE 2023002239 A PE2023002239 A PE 2023002239A PE 2023002239 A PE2023002239 A PE 2023002239A PE 20240693 A1 PE20240693 A1 PE 20240693A1
Authority
PE
Peru
Prior art keywords
tcr
chain variable
variable domain
beta
alpha
Prior art date
Application number
PE2023002239A
Other languages
English (en)
Inventor
Conor Hayes
Linda Hibbert
Nathaniel Liddy
Tara Mahon
Marine Raman
Original Assignee
Immunocore Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunocore Ltd filed Critical Immunocore Ltd
Publication of PE20240693A1 publication Critical patent/PE20240693A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invencion se refiere a receptores de celulas T (TCR) que se unen al peptido restringido al HLA-A 02 GVYDGREHTV (SEQ ID NO: 1) derivado del antigeno de cancer de linea germinal MAGE A4. Dichos TCR pueden comprender mutaciones no naturales dentro de los dominios variables alfa y/o beta con respecto a un TCR de MAGE A4 nativo. Los TCR de la invencion son particularmente adecuados para uso como nuevos reactivos inmunoterapeuticos para el tratamiento de enfermedades malignas. En particular, se refiere a un receptor de celulas T (TCR) recombinante que tiene la propiedad de unirse al complejo GVYDGREHTV (SEQ ID NO: 1) HLA-A 02 y que comprende un dominio variable de cadena alfa de TCR, en donde en el dominio variable de cadena alfa, se selecciona en la secuencia de residuos de aminoacido 27 - 32, 50 - 56 y 91 - 103 y un dominio variable de cadena beta, en donde en el dominio variable de cadena beta, se selecciona en la secuencia de residuos de aminoacido 27 - 31, 49 - 54 y 92 - 107.
PE2023002239A 2016-04-08 2017-04-07 Receptores de celulas t PE20240693A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201606009 2016-04-08
PCT/GB2017/050985 WO2017175006A1 (en) 2016-04-08 2017-04-07 T cell receptors

Publications (1)

Publication Number Publication Date
PE20240693A1 true PE20240693A1 (es) 2024-04-10

Family

ID=58548761

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2018001971A PE20190335A1 (es) 2016-04-08 2017-04-07 Receptores de celulas t
PE2023002239A PE20240693A1 (es) 2016-04-08 2017-04-07 Receptores de celulas t

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2018001971A PE20190335A1 (es) 2016-04-08 2017-04-07 Receptores de celulas t

Country Status (31)

Country Link
US (2) US11505590B2 (es)
EP (2) EP3440105B1 (es)
JP (1) JP7254519B2 (es)
KR (1) KR102473964B1 (es)
CN (1) CN109563148B (es)
AU (2) AU2017246693B2 (es)
BR (1) BR112018070741A2 (es)
CL (1) CL2018002859A1 (es)
CO (1) CO2018011972A2 (es)
CR (1) CR20180531A (es)
CY (1) CY1125331T1 (es)
DK (1) DK3440105T3 (es)
ES (1) ES2914648T3 (es)
HR (1) HRP20220865T1 (es)
HU (1) HUE059159T2 (es)
IL (2) IL308831A (es)
LT (1) LT3440105T (es)
MA (1) MA44608B1 (es)
MD (1) MD3440105T2 (es)
MX (1) MX2018012318A (es)
MY (1) MY198621A (es)
PE (2) PE20190335A1 (es)
PH (1) PH12018502158B1 (es)
PL (1) PL3440105T3 (es)
PT (1) PT3440105T (es)
RS (1) RS63371B1 (es)
SG (1) SG11201808797XA (es)
SI (1) SI3440105T1 (es)
SM (1) SMT202200306T1 (es)
UA (1) UA129144C2 (es)
WO (1) WO2017175006A1 (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7204484B2 (ja) 2016-04-08 2023-01-16 アダプティミューン・リミテッド Ｔ細胞受容体
WO2017174822A1 (en) * 2016-04-08 2017-10-12 Adaptimmune Limited T cell receptors
CA3080546A1 (en) 2017-10-03 2019-04-11 Juno Therapeutics, Inc. Hpv-specific binding molecules
WO2019133443A1 (en) * 2017-12-28 2019-07-04 Janux Therapeutics, Inc. Modified t cell receptors
GB201803750D0 (en) 2018-03-08 2018-04-25 Immunocore Ltd Method
EP3775238A1 (en) * 2018-04-05 2021-02-17 Juno Therapeutics, Inc. Methods of producing cells expressing a recombinant receptor and related compositions
HRP20240176T1 (hr) 2019-01-17 2024-04-12 Immunocore Limited Formulacije
GB201901306D0 (en) 2019-01-30 2019-03-20 Immunocore Ltd Multi-domain binding molecules
GB201901305D0 (en) 2019-01-30 2019-03-20 Immunocore Ltd Specific binding molecules
EP3714941A1 (en) * 2019-03-27 2020-09-30 Medigene Immunotherapies GmbH Mage-a4 tcrs
CN114585646B (zh) * 2019-06-18 2024-09-03 里珍纳龙药品有限公司 Mage-a4 t细胞受体及其使用方法
CR20210687A (es) 2019-06-25 2022-03-03 Gilead Sciences Inc PROTEÍNAS DE FUSIÓN FLT3L-Fc Y MÉTODOS DE USO
US12480958B2 (en) 2019-08-13 2025-11-25 Immatics Biotechnologies Gmbh Method for the characterization of peptide:MHC binding polypeptides
GB201915282D0 (en) * 2019-10-22 2019-12-04 Immunocore Ltd Specific binding molecules
EP4076666A1 (en) 2019-12-18 2022-10-26 F. Hoffmann-La Roche AG Antibodies binding to hla-a2/mage-a4
EP4103285A2 (en) 2020-02-14 2022-12-21 Jounce Therapeutics, Inc. Antibodies and fusion proteins that bind to ccr8 and uses thereof
JP7785696B2 (ja) * 2020-05-18 2025-12-15 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 操作されたｔ細胞受容体および使用の方法
JP2023527293A (ja) * 2020-05-19 2023-06-28 アムジエン・インコーポレーテツド Ｍａｇｅｂ２結合構築物
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
WO2022190007A1 (en) 2021-03-09 2022-09-15 Cdr-Life Ag Rabbit-derived antigen binding protein nucleic acid libraries
CA3210289A1 (en) 2021-03-09 2022-09-15 Anna Maria SOBIERAJ Mage-a4 peptide-mhc antigen binding proteins
US20220389394A1 (en) 2021-05-18 2022-12-08 Gilead Sciences, Inc. METHODS OF USING FLT3L-Fc FUSION PROTEINS
TWI857377B (zh) 2021-10-28 2024-10-01 美商基利科學股份有限公司 嗒-3(2h)-酮衍生物
MX2024005066A (es) 2021-10-29 2024-05-24 Gilead Sciences Inc Compuestos de cd73.
WO2023099606A1 (en) 2021-12-01 2023-06-08 Immunocore Limited Treatment of mage-a4 positive cancer
US12122764B2 (en) 2021-12-22 2024-10-22 Gilead Sciences, Inc. IKAROS zinc finger family degraders and uses thereof
WO2023122581A2 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
PE20242225A1 (es) 2022-03-17 2024-11-19 Gilead Sciences Inc Degradadores de dedos de zinc de la familia ikaros y usos de estos
AU2023256670A1 (en) 2022-04-21 2024-10-17 Gilead Sciences, Inc. Kras g12d modulating compounds
CN117106060A (zh) * 2022-05-17 2023-11-24 香雪生命科学技术（广东）有限公司 一种识别mage的高亲和力t细胞受体及其应用
CA3260083A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. CD73 COMPOUNDS
WO2024038183A1 (en) 2022-08-18 2024-02-22 Immunocore Limited Multi-domain binding molecules
CN120112556A (zh) 2022-08-18 2025-06-06 英美偌科有限公司 多结构域结合分子
TW202413409A (zh) 2022-08-18 2024-04-01 英商英美偌科有限公司 多域結合分子
KR20250070621A (ko) 2022-08-18 2025-05-20 이뮤노코어 리미티드 Mage-a4에 특이적인 t 세포 수용체 융합 단백질
AU2023342450A1 (en) 2022-09-14 2025-03-13 Cdr-Life Ag Mage-a4 peptide dual t cell engagers
KR20250122479A (ko) 2022-12-22 2025-08-13 길리애드 사이언시즈, 인코포레이티드 Prmt5 억제제 및 이의 용도
AU2024252725A1 (en) 2023-04-11 2025-11-06 Gilead Sciences, Inc. Kras modulating compounds
KR20250175331A (ko) 2023-04-21 2025-12-16 길리애드 사이언시즈, 인코포레이티드 Prmt5 억제제 및 이의 용도
US20250042922A1 (en) 2023-06-30 2025-02-06 Gilead Sciences, Inc. Kras modulating compounds
US20250066328A1 (en) 2023-07-26 2025-02-27 Gilead Sciences, Inc. Parp7 inhibitors
US20250100998A1 (en) 2023-07-26 2025-03-27 Gilead Sciences, Inc. Parp7 inhibitors
WO2025054530A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
WO2025054347A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Kras g12d modulating compounds
GB202315181D0 (en) 2023-10-03 2023-11-15 Immunocore Ltd Peptide-HLA binding molecules
TW202530269A (zh) * 2023-10-27 2025-08-01 大陸商北京可瑞生物科技有限公司 基於ｔ細胞受體的多特異性多肽分子及其組合物和用途
WO2025094054A1 (en) 2023-11-01 2025-05-08 Immunocore Limited Method for purifying small multi-domain proteins
US20250154172A1 (en) 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
GB202320012D0 (en) 2023-12-22 2024-02-07 Immunocore Ltd Bispecific molecules
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
GB2641580A (en) 2024-06-07 2025-12-10 T Therapeutics Ltd Tumour-transforming multispecific proteins

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6685698A (en) 1997-03-07 1998-09-22 Sunol Molecular Corporation Fusion proteins comprising bacteriophage coat protein and a single-chain t cell receptor
CA2305630C (en) 1997-10-02 2012-11-06 Sunol Molecular Corporation Soluble single-chain t-cell receptor proteins
EP1117679B9 (en) * 1998-10-02 2010-07-07 Ludwig Institute For Cancer Research Tumor antigens and ctl clones isolated by a novel procedure
ATE411522T1 (de) 1999-12-06 2008-10-15 Univ Illinois Hochaffine t-zellrezeptorproteine und verfahren
WO2001062908A2 (en) 2000-02-22 2001-08-30 Ahuva Nissim Chimeric and tcr phage display libraries, chimeric and tcr reagents and methods of use thereof
IL160359A0 (en) 2001-08-31 2004-07-25 Avidex Ltd Soluble t cell receptor
AU2003289716A1 (en) 2002-09-12 2004-04-30 Incyte Corporation Molecules for diagnostics and therapeutics
CA2501870C (en) 2002-10-09 2013-07-02 Avidex Limited Single chain recombinant t cell receptors
WO2004044004A2 (en) 2002-11-09 2004-05-27 Avidex Limited T cell receptor display
GB0304068D0 (en) * 2003-02-22 2003-03-26 Avidex Ltd Substances
EP2301964A1 (en) 2005-04-01 2011-03-30 Immunocore Ltd. High affinity HIV T cell receptors
CN101287831B (zh) * 2005-09-13 2013-05-15 国立大学法人三重大学 T细胞受体和编码该受体的核酸
GB0908613D0 (en) 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
JP6415322B2 (ja) 2011-09-15 2018-10-31 アメリカ合衆国 Ｈｌａ−ａ１−又はｈｌａ−ｃｗ７−拘束性ｍａｇｅを認識するｔ細胞受容体
CN104144700B (zh) * 2011-10-14 2016-10-19 特瓦制药澳大利亚私人有限公司 抗CD1d的抗体
LT3424947T (lt) 2011-10-28 2021-03-10 Regeneron Pharmaceuticals, Inc. Genetiškai modifikuotos t ląstelių receptorių pelės
GB201223172D0 (en) 2012-12-21 2013-02-06 Immunocore Ltd Method
US10377808B2 (en) * 2013-01-29 2019-08-13 Max-Delbrück-Centrum Für Molekulare Medizin (Mdc) Berlin-Buch High avidity antigen recognizing constructs
CA2906587C (en) 2013-03-13 2023-02-14 Health Research, Inc. Compositions and methods for use of recombinant t cell receptors for direct recognition of tumor antigen
US10927160B2 (en) * 2014-07-09 2021-02-23 The Regents Of The University Of California Engineered invariant natural killer T (iNKT) cells and methods of making and using thereof
CN107074970B (zh) 2014-08-04 2021-07-30 弗雷德哈钦森癌症研究中心 特异性针对wt-1的t细胞免疫疗法
ES2807591T3 (es) 2015-04-13 2021-02-23 Pfizer Receptores de antígeno quimérico dirigidos a antígeno de maduración de células B
DK3430030T5 (da) 2016-03-16 2024-09-23 Immatics Biotechnologies Gmbh Transficerede t-celler og t-cellereceptorer til anvendelse i immunoterapi mod cancer
IL261941B2 (en) 2016-04-01 2023-11-01 Kite Pharma Inc Chimeric antigen and T cell receptors and methods of use

Also Published As

Publication number Publication date
UA129144C2 (uk) 2025-01-29
CY1125331T1 (el) 2025-03-28
PH12018502158A1 (en) 2019-07-15
DK3440105T3 (da) 2022-06-13
HRP20220865T1 (hr) 2022-10-14
US20230322895A1 (en) 2023-10-12
EP4023668A1 (en) 2022-07-06
RU2018135248A (ru) 2020-05-12
SMT202200306T1 (it) 2022-09-14
HUE059159T2 (hu) 2022-10-28
IL262144B2 (en) 2024-04-01
SG11201808797XA (en) 2018-11-29
CR20180531A (es) 2019-06-13
RU2018135248A3 (es) 2020-09-23
KR102473964B1 (ko) 2022-12-06
KR20180132844A (ko) 2018-12-12
MA44608B1 (fr) 2022-06-30
SI3440105T1 (sl) 2022-07-29
JP7254519B2 (ja) 2023-04-10
MY198621A (en) 2023-09-11
LT3440105T (lt) 2022-05-25
WO2017175006A1 (en) 2017-10-12
EP3440105B1 (en) 2022-04-27
CN109563148B (zh) 2022-10-14
US11505590B2 (en) 2022-11-22
CA3020214A1 (en) 2017-10-12
EP3440105A1 (en) 2019-02-13
PT3440105T (pt) 2022-05-31
CN109563148A (zh) 2019-04-02
US20190092834A1 (en) 2019-03-28
AU2017246693A1 (en) 2018-11-22
MA44608A (fr) 2019-02-13
PE20190335A1 (es) 2019-03-07
CL2018002859A1 (es) 2019-04-26
PL3440105T3 (pl) 2022-08-29
IL262144A (en) 2018-11-29
MX2018012318A (es) 2019-07-04
BR112018070741A2 (pt) 2019-02-12
IL308831A (en) 2024-01-01
RS63371B1 (sr) 2022-08-31
ES2914648T3 (es) 2022-06-15
AU2017246693B2 (en) 2022-07-21
MD3440105T2 (ro) 2022-09-30
CO2018011972A2 (es) 2019-02-08
IL262144B1 (en) 2023-12-01
PH12018502158B1 (en) 2024-02-02
AU2022256131A1 (en) 2022-11-24
JP2019516357A (ja) 2019-06-20

Similar Documents

Publication Publication Date Title
PE20240693A1 (es) Receptores de celulas t
MX2024001522A (es) Receptores de celulas t.
MX395153B (es) Receptores de células t.
CL2021001744A1 (es) Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de próstata y otros tipos de cáncer (divisional de la solicitud no. 201800324)
CL2023000562A1 (es) Proteínas de unión a antígeno que se unen específicamente a mage-a
CY1121962T1 (el) Υποδοχεις τ κυτταρου
EA201992536A1 (ru) Tcr и пептиды
MX2025007532A (es) Receptores de antigenos quimericos para el tratamiento del cancer
CL2023000657A1 (es) Péptido que se une al mhc
CR20180492A (es) Células t transfectadas y receptores de células t de utilidad en inmunoterapias contra el cáncer
MX395287B (es) Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos.
CL2017003361A1 (es) Nuevos péptidos y combinación de péptidos para usar en inmunoterapia contra el cáncer esofágico y otros cánceres
BR112018015545A2 (pt) tratamentos de câncer do útero
PE20211300A1 (es) Peptidos y combinacion de peptidos de origen no canonico para el uso en la inmunoterapia contra diferentes tipos de cancer
CR20190072A (es) Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a cd3 y cd123
AR091069A1 (es) Proteinas de union a antigeno dirigidas contra el receptor st2
MX371202B (es) Receptores de células t humanas con alta afinidad modificados por medio de manipulación genética.
PE20191248A1 (es) Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el cancer de ovario y otros tipos de cancer
MX2022004906A (es) Moleculas de union especifica.
AR112601A1 (es) Métodos para predecir la utilidad de modificaciones aminoacídicas específicas de enfermedad para inmunoterapia
CL2023000659A1 (es) Péptido que se une al mhc
MX2021011698A (es) Moleculas de unión específicas.
CL2019001537A1 (es) Nuevos receptores de células t y terapia inmunológica que los utiliza.
AR109345A1 (es) Receptores de linfocitos t e inmunoterapia basada en el uso de los mismos
EA201992002A1 (ru) Т-клеточные рецепторы и иммунная терапия prame-положительных раковых заболеваний с их применением